AVEO · Aveo Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $42.30M | $6.02M | $28.80M | $2.52M | $7.58M | $2.52M |
| Cost of Revenue | $0 | - | - | - | - | - |
| Gross Profit | $42.30M | - | - | - | - | - |
| R&D | $26.30M | $22.68M | $17.96M | $20.65M | $25.18M | $23.70M |
| SG&A | $60.81M | $22.22M | $11.21M | $10.78M | $9.14M | $8.21M |
| Total Operating Expenses | $44.90M | $44.90M | $29.17M | $30.77M | $36.39M | $31.91M |
| D&A | $67.0K | $21.0K | - | $0 | $0 | $30.0K |
| Operating Income | ($49.55M) | ($38.88M) | ($374.0K) | ($25.36M) | ($28.81M) | ($29.39M) |
| Interest Expense | - | $1.60M | $1.81M | $2.19M | $2.37M | $1.95M |
| Income Tax | $0 | $0 | $0 | $0 | $101.0K | $101.0K |
| Net Income | ($53.34M) | ($35.58M) | $9.39M | ($5.33M) | ($65.03M) | ($26.89M) |
| EPS - Basic | ($1.63) | ($1.66) | $0.61 | ($0.39) | - | - |
| EPS - Diluted | ($1.63) | ($1.66) | $0.61 | ($0.39) | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $70.54M | $61.76M | $29.79M | $24.43M | $14.95M | $15.10M |
| Accounts Receivable | $9.81M | $1.20M | $1.63M | $3.03M | $402.0K | $1.03M |
| Inventory | $1.66M | - | - | - | - | - |
| Accounts Payable | $2.71M | $3.38M | $1.47M | $3.50M | $2.44M | $2.19M |
| Current Assets | $104.74M | $65.51M | $50.60M | $27.93M | $50.18M | $26.32M |
| Total Assets | $105.34M | $66.91M | $50.60M | $27.93M | $50.20M | $27.29M |
| Current Liabilities | $18.73M | $16.95M | $21.12M | $18.12M | $32.12M | $10.35M |
| Long-term Debt | - | - | $16.20M | - | - | - |
| Total Liabilities | $59.47M | $31.62M | $35.75M | $55.16M | $90.96M | $29.21M |
| Stockholders' Equity | $45.87M | $35.29M | $14.85M | ($27.23M) | ($40.76M) | ($1.92M) |
| Retained Earnings | ($674.55M) | ($621.21M) | ($585.62M) | ($595.01M) | ($586.97M) | ($521.92M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($57.26M) | ($37.98M) | ($2.92M) | ($31.07M) | ($19.16M) | ($31.07M) |
| Investing Cash Flow | ($16.87M) | $17.70M | ($17.92M) | ($764.0K) | ($10.40M) | ($764.0K) |
| Financing Cash Flow | $82.90M | $52.26M | $26.19M | $20.29M | $29.42M | $20.29M |
| CapEx | $0 | $363.0K | - | - | - | $7.0K |
| Free Cash Flow | ($57.26M) | ($38.35M) | - | - | - | ($31.07M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 100.0% | - | - | - | - | - |
| Operating margin | -117.2% | -645.9% | -1.3% | -1008.2% | -380.1% | -1168.7% |
| EBITDA margin | -117.0% | -645.6% | - | -1008.2% | -380.1% | -1167.5% |
| Net margin | -126.1% | -591.2% | 32.6% | -211.9% | -858.0% | -1069.1% |
| Free cash flow margin | -135.4% | -637.1% | - | - | - | -1235.5% |
| FCF / Net income | 1.07 | 1.08 | - | - | - | 1.16 |
| R&D / Revenue | 62.2% | 376.8% | 62.4% | 821.2% | 332.2% | 942.5% |
| SG&A / Revenue | 143.8% | 369.1% | 38.9% | 428.7% | 120.6% | 326.2% |
| Effective tax rate | - | - | 0.0% | - | - | - |
| Return on assets | -50.6% | -53.2% | 18.6% | -19.1% | -129.5% | -98.5% |
| Return on equity | -116.3% | -100.8% | 63.2% | 19.6% | 159.5% | 1398.2% |
| Return on invested capital | - | - | -1.2% | - | - | - |
| Liquidity | ||||||
| Current ratio | 5.59 | 3.87 | 2.40 | 1.54 | 1.56 | 2.54 |
| Quick ratio | 5.50 | 3.87 | 2.40 | 1.54 | 1.56 | 2.54 |
| Cash ratio | 3.77 | 3.64 | 1.41 | 1.35 | 0.47 | 1.46 |
| Leverage | ||||||
| Debt / Equity | - | - | 1.09 | - | - | - |
| Debt / Assets | - | - | 0.32 | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | -24.2x | -0.2x | -11.6x | -12.1x | -15.1x |
| Equity multiplier | 2.30 | 1.90 | 3.41 | -1.03 | -1.23 | -14.19 |
| Liabilities / Assets | 0.56 | 0.47 | 0.71 | 1.97 | 1.81 | 1.07 |
| Efficiency | ||||||
| Asset turnover | 0.40 | 0.09 | 0.57 | 0.09 | 0.15 | 0.09 |
| Inventory turnover | 0.00 | - | - | - | - | - |
| Days sales outstanding | 85d | 73d | 21d | 439d | 19d | 149d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 602.7% | -79.1% | 1044.9% | -66.8% | 201.4% | -86.8% |
| Revenue CAGR (3y) | 156.2% | -7.4% | 125.4% | -49.1% | -25.2% | 24.8% |
| Revenue CAGR (5y) | 75.9% | -20.6% | 9.7% | 14.2% | -17.0% | -34.4% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -27.5% | -10294.9% | 98.5% | 12.0% | 2.0% | -136.5% |
| Net income growth (YoY) | -49.9% | - | - | 91.8% | -141.8% | -79.2% |
| EPS growth (YoY) | 1.8% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -49.3% | - | - | - | - | -70.2% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 30.0% | 137.7% | - | 33.2% | -2019.8% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$83.14M totalProduct Gross$45.67M · 54.9%
Product$38.87M · 46.8%
Royalty$3.42M · 4.1%
Collaboration And Licensing$1.97M · 2.4%
Product Sales Discounts And Allowances($6.79M) · -8.2%
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
-5.58
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing AVEO PHARMACEUTICALS against the 5 most active filers in the same SIC group.